Aldeyra Therapeutics (ALDX) Interest Coverage Ratio (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Interest Coverage Ratio came in at 7.57 in Q1 2026, down 491.83% YoY from 1.93 in Q1 2025, and up 27.58% on a QoQ basis from 10.45 in Q4 2025.
Aldeyra Therapeutics (ALDX) Interest Coverage Ratio (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 14 years of Interest Coverage Ratio data on file, last reported at 7.57 in Q1 2026.
- Quarterly Interest Coverage Ratio fell 491.83% year-over-year to 7.57 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 13.01 (down 73.52% YoY) and the FY2025 annual result came in at 5.34, up 56.62% from the prior year.
- Interest Coverage Ratio advanced to 7.57 in Q1 2026, from 10.45 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 0.59 in Q2 2023 to a low of 42.05 in Q4 2023.
- A 5-year average of 11.82 and a median of 7.57 in 2026 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio jumped 99.01% — and 2024, when it slumped 6279.56%.
- Tracing ALDX's Interest Coverage Ratio over 5 years: stood at 19.23 in 2022, then plunged by 118.66% to 42.05 in 2023, then soared by 33.97% to 27.77 in 2024, then jumped by 62.36% to 10.45 in 2025, then rose by 27.58% to 7.57 in 2026.
- The last three Interest Coverage Ratio figures came in at 7.57 (Q1 2026), 10.45 (Q4 2025), and 1.17 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 2.82 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.08 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.42 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 76.86 |
| 10 | Aldeyra Therapeutics | 91.08 Mn | 91.08 Mn | - | -254,369.87 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.00 |
| Mar 31, 2026 | -7.57 |
| Dec 31, 2025 | -10.45 |
| Sep 30, 2025 | -1.17 |
| Jun 30, 2025 | -8.53 |
| Mar 31, 2025 | -1.28 |
| Dec 31, 2024 | -27.77 |
| Sep 30, 2024 | -2.18 |
| Jun 30, 2024 | -37.70 |
| Mar 31, 2024 | -18.84 |
| Dec 31, 2023 | -42.05 |
| Sep 30, 2023 | -1.27 |
| Jun 30, 2023 | -0.59 |
| Mar 31, 2023 | -0.64 |
| Dec 31, 2022 | -19.23 |
| Sep 30, 2022 | -3.02 |
| Jun 30, 2022 | -11.07 |
| Mar 31, 2022 | -7.50 |
| Dec 31, 2021 | -1,945.72 |
| Sep 30, 2021 | -1.29 |